Navigation Links
Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
Date:3/6/2017

Today, an article co-authored by founders of Phase Genomics was published in Nature Genetics, summarizing the assembly of the most contiguous de novo mammalian genome to-date. The ultra-long-range scaffolds in this goat genome were made possible by Phase Genomics’ revolutionary genome scaffolding technology now called Proximo™ Hi-C – the first commercial offering of in vivo Hi-C based genome assembly and the commercial successor to the Lachesis method described in the article. The study was spearheaded by a group of researchers from the USDA, NHGRI, and Virginia State University, together with Phase Genomics and other commercial entities.

“We are pleased to have the opportunity to share the results of this groundbreaking project with Nature Genetics readers,” said company CEO, Ivan Liachko. “This paper highlights a fundamental advancement in genome assembly and I'm thrilled to see the animal community gain such an amazing resource.”

The Proximo Hi-C scaffolding platform is the fastest and most affordable solution for end-to-end scaffolding of de novo genomes. Genomes assembled without this process are fragmented and often omit critical biological information.

For this project, Pacific Biosciences long-read shotgun sequencing, Illumina short reads, and BioNano Irys optical mapping were used to generate a draft assembly. The Proximo Hi-C process was then used in combination with custom analysis to create chromosome-level scaffolds.

“We saw similar results in our work with Phase Genomics on plants and look forward to publishing similar outcomes soon,” said Prof. Jeff Maughan, a plant researcher at Brigham-Young University. “The level of genome completeness and contiguity yielded by this technology has transformed how we view genome projects and has enabled us to ask new biological questions.”

Interested parties can learn more about Proximo Hi-C and other Phase Genomics services by visiting their website at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14121855.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients
2. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
3. BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)
4. VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)
5. OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
6. Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
7. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma
8. Roche selects Vivonoetics to provide advanced respiratory assessment for the FIREFISH Phase II multicenter clinical trial in infants with Spinal Muscular Atrophy Type 1.
9. Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
10. Phase Genomics Announces Commercial Availability of Rapid End-to-End Genome Assembly Service
11. Symbios Announces National Science Foundation SBIR Phase IIB Award to Commercialize Plasma Oxidation Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... A ... mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying ... on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
(Date:5/15/2019)... FALLS, Wis. (PRWEB) , ... May 16, 2019 ... ... oil and water mixtures. As a result, food and beverage products rely on ... today, consumers demand more natural sounding label declarations. This paradigm shift triggers food ...
(Date:5/4/2019)... PAULO, Brazil (PRWEB) , ... May 03, 2019 ... ... lecture given by the President of the Dakila Pesquisas Association, the scientist and ... the Councilmen 2019, in Brasília (DF). Urandir detailed the results of some research ...
Breaking Biology Technology:
(Date:6/11/2019)... ... , ... Improved Pharma LLC announces the publication of “Predictive and Accelerated Formulation ... was published online on April 29th, 2019. The authors are Stephen R. Byrn ... Purdue University. , The article is the most recent addition to a theme dedicated ...
(Date:6/4/2019)... ... June 04, 2019 , ... ... appointment of Susan Murphy as the new President of Molecular Devices, replacing Greg ... Devices’ parent company, Danaher Corporation. , Since joining Molecular Devices in a scientific ...
(Date:6/1/2019)... ... May 31, 2019 , ... ... Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. ... securing value-added institutional investors who bring significant financial and business resources to bear ...
Breaking Biology News(10 mins):